What question did this study set out to answer?

This analysis aims to assess infection incidence and its impact on survival in multiple myeloma patients receiving CAR T-cell therapy.

December 8, 2025BloodOpen Access

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

View Full Paper

Ask AI

Bookmark

Authors

MAMuhammad Bilal AbidAga Khan University AMAbu‐Sayeef MirzaUniversity of South Florida LGLohith GowdaYale Cancer Center

Discussion

Member takes

Implication

Real-world analysis reveals infection prevalence and risk factors in relapsed refractory multiple myeloma patients receiving CAR T-cell therapy, suggesting the need for preventive strategies.

Key Points

This analysis aims to assess infection incidence and its impact on survival in multiple myeloma patients receiving CAR T-cell therapy.
Analyzed infection density and types in patients post-CAR-T infusion.
Utilized multivariable Cox proportional hazards models to identify risk factors for infections.
Studied 807 patients from CIBMTR between March 2021 and December 2023.
114 (14.1%) patients developed infections within 30 days post-infusion.
226 (28%) patients had infections within 100 days post-infusion, with an overall infection density of 0.49 per 100 patient-days.
Intravenous immunoglobulin showed a survival advantage (HR, 0.52; 95%CI, 0.38-0.72).

Cite This Study

Abid et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4ca https://doi.org/10.1182/blood-2025-716

View Full Paper

Ask AI

Bookmark

Implication

Real-world analysis reveals infection prevalence and risk factors in relapsed refractory multiple myeloma patients receiving CAR T-cell therapy, suggesting the need for preventive strategies.

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Discussion

Member takes

Implication

Key Points

Cite This Study

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider